CEO Executive AssistantScientific Advisory Boards (SABs) are a distinctive asset in biotech organizations. A well-constituted SAB provides external scientific perspective, discipline expertise that complements internal capabilities, clinical development insight, and, for public biotechs, investor-credibility signals that can influence capital raising. Managing an SAB effectively requires both scientific credibility and relationship management expertise that the CEO alone cannot fully provide.
Biotech CEOs who manage their SABs without a clear delegation structure find themselves spending significant time on SAB logistics, preparation, and follow-up while potentially not leveraging SAB members optimally for the scientific and strategic questions that matter most. These delegation strategies help biotech CEOs get maximum value from their SABs while building the organizational capacity to manage the SAB relationship professionally.
Strategy 1: Assign SAB Management to the CSO with CEO Partnership
The Chief Scientific Officer is the most appropriate primary owner of the SAB relationship. The CSO has the scientific depth to engage meaningfully with SAB members on technical questions, the organizational credibility to represent the company’s scientific programs accurately, and the ongoing scientific relationships that make SAB engagement substantive.
The CEO’s SAB role should be defined explicitly: chair or co-chair SAB meetings, set the agenda for strategic SAB discussions, maintain personal relationships with the two or three most influential SAB members, and engage the SAB for input on company-level strategic questions. The CSO manages the SAB between meetings, coordinates advisory requests, and prepares the scientific content for SAB meetings.
This division ensures the SAB is managed professionally by the person with the deepest relevant expertise while keeping the CEO engaged at the strategic moments where CEO involvement adds value.
Strategy 2: Delegate SAB Meeting Preparation to the Scientific Leadership Team
SAB meetings require extensive preparation: scientific updates for each active program, pre-reads on strategic questions to be discussed, logistics coordination, and pre-meeting briefings for SAB members. All of this preparation can and should be delegated.
The CSO leads a pre-SAB preparation process that involves all relevant program leads and scientific team leaders. Each program lead prepares their program update; the CSO integrates the updates into a coherent scientific narrative; the CEO reviews the agenda and strategic discussion topics.
The CEO’s meeting preparation should focus on: the strategic questions they want the SAB to address, any organizational context they want to provide (financing, partnership, competitive landscape), and any specific SAB member relationships requiring personal outreach. The CEO should not be preparing scientific content or managing meeting logistics.
Strategy 3: Use SAB Members as Delegation Extensions
SAB members can serve as expert resources for specific scientific questions between meetings, functioning as a delegation extension for specialized expertise the company lacks internally. Managing this advisory relationship effectively requires a protocol for how SAB members are engaged for ad hoc consultation.
Define a protocol for engaging SAB members between meetings: what questions can the CSO or program leads direct to SAB members without CEO involvement, how honoraria and expenses are managed for ad hoc consultations, and what questions should be reserved for the next full SAB meeting rather than addressed through ad hoc engagement.
The CEO should not be the coordinator of ad hoc SAB consultations. The CSO manages this relationship channel, ensuring SAB members are engaged appropriately and that the interactions are documented and productive.
Strategy 4: Align SAB Membership with Delegation Gaps
The composition of the SAB should reflect the scientific and clinical expertise gaps that the CEO and CSO want to fill through external advisory input. If the company is weak in biostatistics for adaptive trial design, a statistical expert on the SAB fills a delegation gap. If the company has deep internal oncology expertise but limited cardiovascular knowledge and is considering an indication expansion, cardiovascular KOLs on the SAB provide needed input.
Actively managing SAB composition, including rotating members whose expertise is less relevant as programs advance and adding members whose expertise is critical for upcoming development decisions, is a CEO and CSO strategy decision. The operational management of SAB membership transitions belongs to the CSO.
For context on how SAB management connects to the broader scientific team delegation structure, see pharma CEO clinical ops, which covers how external expert input through Medical Affairs and advisory boards can complement internal scientific and clinical leadership.
Strategy 5: Leverage the SAB for Investor Credibility with Managed CEO Involvement
For public biotechs and clinical-stage private companies raising capital, a distinguished SAB sends a credibility signal to investors. Investors read SAB credentials; they also watch how the SAB is used and whether its members speak publicly about their involvement with the company.
The CEO’s role in managing the SAB’s investor credibility function includes: ensuring the SAB composition is genuinely distinguished and relevant (not a vanity board), working with the Head of IR to appropriately feature SAB members in investor materials where their engagement is authentic, and coordinating with the CSO when SAB members are willing to speak at investor conferences or participate in investor days.
The actual management of SAB member investor relations participation, including the logistics, consent protocols, and content review, should be managed by the Head of IR and the CSO together, not by the CEO personally.
Strategy 6: Delegate SAB Feedback Integration
The most underutilized dimension of SAB management is the integration of SAB feedback into scientific program decisions after meetings. Without a systematic feedback integration process, SAB advice is acknowledged but not acted on, which eventually undermines SAB members’ motivation to engage seriously.
Assign the CSO responsibility for the post-SAB meeting integration process: documenting the key scientific recommendations from the SAB, routing each recommendation to the relevant program lead for response, tracking which recommendations have been implemented and which have been set aside with documented rationale, and briefing the SAB Chair on the organization’s response to the prior meeting’s input.
The CEO should receive a summary of significant SAB recommendations and the scientific team’s response, but should not be the one managing the integration process. This is the CSO’s domain.
Strategy 7: Manage SAB Dynamics Through the CSO
SABs are groups of accomplished scientists who sometimes have strong and divergent views. Managing SAB dynamics, including ensuring all members’ perspectives are heard, navigating disagreements among SAB members, and handling the occasional difficult SAB member relationship, requires interpersonal management skill.
The CSO is the appropriate owner of SAB relationship management. The CEO’s involvement in SAB dynamics should be limited to managing the relationship with the SAB Chair (typically a direct CEO relationship) and providing strategic input on any significant SAB relationship challenges that have organizational implications.
When SAB members disagree significantly about a scientific direction the company is pursuing, this can become a strategic governance question that requires CEO engagement. These situations should be brought to the CEO by the CSO with a clear framing of the scientific question and the options for resolution.
According to Harvard Business Review research on scientific advisory governance, advisory boards provide the most value to organizations when they have clear mandates, structured engagement processes, and organizational leaders who take their input seriously and communicate how it has been used. The delegation structure above creates exactly these conditions.
See pharma CEO delegation guide for a comprehensive framework connecting SAB management to the full range of pharma CEO external stakeholder delegation strategies.
Measuring SAB Delegation Effectiveness
The effectiveness of SAB management delegation can be assessed through several signals:
- SAB meeting preparation quality (are materials substantive and on time?)
- SAB member engagement quality (are members intellectually engaged or going through the motions?)
- Post-meeting feedback integration (are SAB recommendations tracked and responded to?)
- SAB retention (are distinguished members re-engaging rather than quietly disengaging?)
- CEO time efficiency (is the CEO’s SAB engagement concentrated in strategic moments rather than logistics?)
An SAB that is meeting regularly, engaging substantively, and whose input is being genuinely integrated into scientific decisions is a well-delegated SAB. One where meetings are poorly prepared, members feel their input is not used, and the CEO is spending time on logistics rather than strategy is a delegation failure.
Building an effectively delegated SAB management function is an investment in both scientific quality and organizational capability. The CSO and scientific leadership team who manage the SAB professionally develop better external relationships, stronger scientific governance instincts, and greater credibility with the expert community that is central to biotech success.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.